NorthCrest Asset Management and
Pallas Capital Advisors have increased their stakes in
Biogen Inc. (NASDAQ:BIIB), while
Nuveen Asset Management has decreased its share.
H.C. Wainwright has reiterated its buy rating due to potential in nephrology.
Biogen has announced Q1 2025 financial results on May 1, 2025. Their recent investment in the RNAi Therapy through a partnership with
City Therapeutics is promising, leading to a 5.7% soar in stock value but was later followed by a downturn after the earnings report. Q1 Sales targets were surpassed and their work on Lupus treatment is proceeding well. The FDA accepted their Biologics License Application for the treatment of early Alzheimer’s disease. Analysts view Biogen as a good investment, commending its revenue growth. However, they have lowered their profit outlook amidst their deal for an epilepsy drug. The stock is now seen as a value play.
Biogen is set to transform the Kendall Square Research Hub with a 580,000 sq ft Innovation Powerhouse. Despite some setbacks - Alzheimer’s and multiple sclerosis (MS) challenges and a regulatory update from the EU on the Alzheimer’s drug - Biogen continues to show promise. Biogen is receiving new investment from significant entities.
Biogen BIIB News Analytics from Wed, 30 Oct 2024 07:00:00 GMT to Sat, 14 Jun 2025 09:49:38 GMT -
Rating 5
- Innovation 8
- Information 9
- Rumor -5
